MYBPC3 and cardiomyopathy: It has been suggested that titin and MyBP-C aggregates can accumulate intracellularly and inhibit the ubiquitin–proteasome system, thereby disrupting protein quality control mechanisms in cardiomyopathies [8,15,41,42,43,44,45].